Revance Therapeutics, Inc.
RVNC
RVNC was delisted on the 5th of February, 2025.
182 hedge funds and large institutions have $1.7B invested in Revance Therapeutics, Inc. in 2022 Q3 according to their latest regulatory filings, with 45 funds opening new positions, 67 increasing their positions, 40 reducing their positions, and 22 closing their positions.
163% more call options, than puts
Call options by funds: $239M | Put options by funds: $90.9M
133% more capital invested
Capital invested by funds: $731M → $1.7B (+$972M)
105% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 22
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
68% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 40
13% more funds holding
Funds holding: 161 → 182 (+21)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$70.2M |
| 2 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$27.3M |
| 3 |
Holocene Advisors
New York
|
+$21.6M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$17.3M |
| 5 |
Two Sigma Investments
New York
|
+$15.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
-$27.5M |
| 2 |
JP Morgan Chase
New York
|
-$25.1M |
| 3 |
Jennison Associates
New York
|
-$13.9M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$8.92M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$8.37M |
RVNC Hedge Fund Activity: Q3 2022 in Review
182 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q3 2022, worth a combined $1.7B — up 133% from $731M a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new RVNC positions and 22 closed out — a net gain of 23 holders — while 67 added to existing stakes and 40 trimmed.
The largest buyer was Capital World Investors, adding an estimated $70.2M. The largest seller was HealthCor Management, cutting an estimated $27.5M.
- 182 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q3 2022, up from 161 in Q2 2022.
- Funds reported $1.7B of Revance Therapeutics, Inc. stock for Q3 2022, up 133% quarter-over-quarter.
- 45 funds opened new Revance Therapeutics, Inc. positions in Q3 2022 and 22 closed out, a net change of +23 holders.
- The largest Revance Therapeutics, Inc. buyer in Q3 2022 was Capital World Investors, an estimated $70.2M added.
- The largest Revance Therapeutics, Inc. seller in Q3 2022 was HealthCor Management, an estimated $27.5M sold.
Based on aggregated 13F filings for Q3 2022.